2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
Executive Summary
After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.
You may also be interested in...
A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials
The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.
A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials
The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.
For Brand Drugs, Doom And Gloom In 2010
With sluggish pharmaceutical sales growth due to generic uptake, fewer patient visits to doctors and less use of chronic medications - 2010 was a dismal year for brand drugs, IMS data show.